Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 98985Y108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
EcoR1 Capital, LLC
13D/A
|
30.7% |
11/19/2025
Event 11/16/2025
|
||
| EcoR1 Capital, LLC | 30.7% | |||
| Oleg Nodelman | 30.7% | |||
| EcoR1 Capital Fund Qualified, L.P. | 28.8% | |||
|
Rubric Capital Management LP
13G/A
|
9.5% |
5/15/2026
Event 3/31/2026
|
||
| Rubric Capital Management LP | 9.5% | |||
| David Rosen | 9.5% | |||
|
Perceptive Advisors LLC
13G
|
5.4% |
4/15/2026
Event 4/8/2026
|
||
| Perceptive Advisors LLC | 5.4% | |||
| Joseph Edelman | 5.4% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 5.4% | |||
|
Biotechnology Value Fund L P
13G/A
|
5.2% |
11/14/2025
Event 9/30/2025
|
||
| Biotechnology Value Fund L P | 2.7% | |||
| BVF I GP LLC | 2.7% | |||
| Biotechnology Value Fund II LP | 2.1% | |||
| BVF II GP LLC | 2.1% | |||
| Biotechnology Value Trading Fund OS LP | 0.3% | |||
| BVF Partners OS Ltd. | 0.3% | |||
| BVF GP Holdings LLC | 4.9% | |||
| BVF Partners L P/IL | 5.2% | |||
| BVF Inc/IL | 5.2% | |||
| Lampert Mark N | 5.2% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
Redmile Group, LLC
13G/A
|
4.9% |
11/14/2025
Event 9/30/2025
|
||
| Redmile Group, LLC | 4.9% | |||
| Jeremy C. Green | 4.9% | |||
| BlackRock, Inc. 13G/A | 4.8% |
7/16/2025
Event 6/30/2025
|
||
| Morgan Stanley 13G/A | 3.4% |
2/12/2026
Event 12/31/2025
|
||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 1.32 k | $35.0 k |
| 2026 Q2 | 209 | 70.6 M | $1.86 B |
| 2026 Q1 | 224 | 70.3 M | $1.76 B |
| 2025 Q4 | 226 | 71.5 M | $1.88 B |
| 2025 Q3 | 193 | 73.7 M | $1.26 B |
| 2025 Q2 | 190 | 75.9 M | $953 M |
| 2025 Q1 | 193 | 70.6 M | $841 M |
| 2024 Q4 | 180 | 66.5 M | $973 M |
| 2024 Q3 | 170 | 66.6 M | $835 M |
| 2024 Q2 | 172 | 72.5 M | $617 M |
| 2024 Q1 | 182 | 78.3 M | $824 M |
| 2023 Q4 | 168 | 70.0 M | $727 M |
| 2023 Q3 | 150 | 62.5 M | $396 M |
| 2023 Q2 | 144 | 63.4 M | $548 M |
| 2023 Q1 | 123 | 56.7 M | $513 M |
| 2022 Q4 | 103 | 55.3 M | $434 M |
| 2022 Q3 | 1 | 78.4 k | $482 k |